全球癌症基因治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

预计癌症基因治疗市场将从 2025 年的 61.6 亿美元成长到 2034 年的 298.6 亿美元，2026 年至 2034 年的复合年增长率为 19.17%。

受分子生物学和基因工程领域进步的推动，全球癌症基因治疗市场正经历快速成长。全球癌症发生率的不断攀升加速了创新治疗方法的研究。基因治疗透过纠正或替换缺陷基因，提供标靶治疗方案，从而提高治疗的精准度。对肿瘤学研究和临床试验投入的增加，也大大促进了市场的发展。

关键成长要素包括病毒载体技术和基于CRISPR的基因编辑工具的突破性进展。个人化医疗的日益普及正在推动对基因治疗方法的需求。新型基因疗法的监管核准将进一步促进创新。此外，生技公司与研究机构之间的合作正在加速产品商业化和市场扩张。

展望未来，随着递送系统和安全性方面的不断进步，市场预计将持续成长。公众意识的提高和报销机制的完善将加速其普及。新兴市场不断完善的癌症治疗基础设施也带来了新的机会。随着基因编辑技术的研究不断进步，癌症基因疗法有望成为癌症治疗领域的变革性力量。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球癌症基因治疗市场：依治疗方法

• 市场分析、洞察与预测
• 溶瘤病毒疗法
• 基因诱导免疫疗法
• 基因转移

第五章：全球癌症基因治疗市场：依最终用途划分

• 市场分析、洞察与预测
• 研究机构
• 生物製药公司
• 诊断中心
• 其他的

第六章 全球癌症基因治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Abeona Therapeutics Inc
  • Asklepios BioPharmaceutical Inc
  • Altor Bioscience Corp
  • Bluebird Bio Inc
  • BioCancell Therapeutics Inc
  • Celgene Corporation
  • Elevate Bio Inc
  • GlaxoSmithKline Plc
  • Genelux Corporation
  • GenVec Inc
  • Introgen Therapeutics Inc
  • Merck KGaA
  • OncoGenex Pharmaceuticals Inc

The Cancer Gene Therapy Market size is expected to reach USD 29.86 Billion in 2034 from USD 6.16 Billion (2025) growing at a CAGR of 19.17% during 2026-2034.

The Global Cancer Gene Therapy Market is witnessing rapid growth due to advancements in molecular biology and genetic engineering. Increasing prevalence of cancer worldwide has accelerated research in innovative treatment approaches. Gene therapy offers targeted solutions by modifying or replacing defective genes, improving treatment precision. Rising investments in oncology research and clinical trials are significantly supporting market development.

Key growth drivers include breakthroughs in viral vector technology and CRISPR-based gene editing tools. Expanding adoption of personalized medicine enhances the demand for gene-based therapies. Regulatory approvals of novel gene therapies encourage further innovation. Additionally, collaborations between biotechnology firms and research institutions accelerate product commercialization and market expansion.

Looking ahead, the market is expected to grow with ongoing advancements in delivery systems and safety profiles. Increased awareness and improved reimbursement frameworks will facilitate adoption. Emerging markets with expanding oncology infrastructure present new opportunities. As research continues to refine gene-editing technologies, cancer gene therapy is poised to become a transformative force in oncology treatment.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Therapy

• Oncolytic Virotherapy
• Gene Induced Immunotherapy
• Gene Transfer

By End Use

• Research Institutes
• Biopharmaceutical Companies
• Diagnostic Centers
• Others

COMPANIES PROFILED

• Abeona Therapeutics Inc, Asklepios BioPharmaceutical Inc, Altor Bioscience Corp, Bluebird Bio Inc, BioCancell Therapeutics Inc, Celgene Corporation, Elevate Bio Inc, GlaxoSmithKline plc, Genelux Corporation, GenVec Inc, Introgen Therapeutics Inc, Merck KGaA, OncoGenex Pharmaceuticals Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER GENE THERAPY MARKET: BY PRODUCT THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Therapy
• 4.2. Oncolytic Virotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Gene Induced Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Gene Transfer Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER GENE THERAPY MARKET: BY END USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End Use
• 5.2. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER GENE THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product Therapy
  • 6.2.2 By End Use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product Therapy
  • 6.3.2 By End Use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product Therapy
  • 6.4.2 By End Use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product Therapy
  • 6.5.2 By End Use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product Therapy
  • 6.6.2 By End Use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CANCER GENE THERAPY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abeona Therapeutics Inc
  • 8.2.2 Asklepios BioPharmaceutical Inc
  • 8.2.3 Altor Bioscience Corp
  • 8.2.4 Bluebird Bio Inc
  • 8.2.5 BioCancell Therapeutics Inc
  • 8.2.6 Celgene Corporation
  • 8.2.7 Elevate Bio Inc
  • 8.2.8 GlaxoSmithKline Plc
  • 8.2.9 Genelux Corporation
  • 8.2.10 GenVec Inc
  • 8.2.11 Introgen Therapeutics Inc
  • 8.2.12 Merck KGaA
  • 8.2.13 OncoGenex Pharmaceuticals Inc